Linked Life Data

9407562

Source:http://linkedlifedata.com/resource/pubmed/id/9407562

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1998-1-8
pubmed:abstractText
The hypotheses tested in this study were that during acute asthma exacerbations (1) exhaled nitric oxide concentrations [eNO] are a more sensitive, noninvasive indicator of asthma disease activity than serum markers of inflammation such as eosinophil cationic protein (ECP) or soluble interleukin 2 receptor (sIL2R), and (2) elevated [eNO] are reduced after treatment with glucocorticoids (GC). Peak eNO levels were measured by chemiluminescence during slow expiration. Seven asthmatic subjects (mean age 11 yrs; mean morning FEV1 65% predicted) receiving inhaled GC, and with no radiographic evidence of acute sinusitis, were studied before and after a course of oral GC. Measurements of [eNO], ECP and sIL2R levels, and FEV1% were obtained before and after a course of GC. Six atopic nonasthmatic subjects (mean age 12 years; mean FEV1 94% predicted) and seven normal subjects (mean age 13 years; mean FEV1 100% predicted) were studied. The mean peak [eNO] level (parts per billion: ppb) for the asthma subjects before treatment (52 +/- 5 ppb SEM) was greater than the value for both nonasthmatic atopic and normal subjects (16 +/- 2 ppb and 14 +/- 2 ppb SEM, respectively; P < 0.0001). There was no significant difference in ECP or sIL2R values between asthmatic subjects and either atopic or normal subjects (P > 0.05). Baseline pre-GC treatment ECP levels in the asthmatic subjects were significantly higher (P < 0.002) than post-GC treatment values. The mean peak [eNO] level in the asthmatic subjects declined after oral GC treatment to 14 +/- 1 ppb (P < 0.0002) and was less than 2 ppb different from either control group (P > 0.75). We conclude that [eNO] is a more sensitive marker of asthma disease activity than ECP and sIL2R levels. In addition, [eNO] appears to be a more useful indicator of the beneficial response to GC therapy than these other measurements in pediatric asthma.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
8755-6863
pubmed:author
pubmed:issnType
Print
pubmed:volume
24
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
305-11
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed-meshheading:9407562-Acute Disease, pubmed-meshheading:9407562-Adolescent, pubmed-meshheading:9407562-Anti-Inflammatory Agents, pubmed-meshheading:9407562-Asthma, pubmed-meshheading:9407562-Biological Markers, pubmed-meshheading:9407562-Blood Proteins, pubmed-meshheading:9407562-Breath Tests, pubmed-meshheading:9407562-Case-Control Studies, pubmed-meshheading:9407562-Child, pubmed-meshheading:9407562-Drug Monitoring, pubmed-meshheading:9407562-Eosinophil Granule Proteins, pubmed-meshheading:9407562-Female, pubmed-meshheading:9407562-Forced Expiratory Volume, pubmed-meshheading:9407562-Humans, pubmed-meshheading:9407562-Inflammation Mediators, pubmed-meshheading:9407562-Male, pubmed-meshheading:9407562-Nitric Oxide, pubmed-meshheading:9407562-Receptors, Interleukin-2, pubmed-meshheading:9407562-Ribonucleases, pubmed-meshheading:9407562-Sensitivity and Specificity, pubmed-meshheading:9407562-Steroids
pubmed:year
1997
pubmed:articleTitle
Comparison of exhaled nitric oxide, serum eosinophilic cationic protein, and soluble interleukin-2 receptor in exacerbations of pediatric asthma.
pubmed:affiliation
Department of Pediatrics, National Jewish Medical and Research Center, Denver, CO 80206, USA.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, U.S. Gov't, P.H.S.